NCT06700213Completed
Guideline Directed Medical Therapy in Patients With Heart Failure
Source: ClinicalTrials.gov · Last updated 25 Sept 2025
Brief summary (registry, in English)
The TEAM-MGH study will formerly evaluate impact of the GDMT Clinic versus matched usual care patients on the proportion of GDMT administration over a 12 week period in approximately 300 total patients with HF across the spectrum of LVEF (with a minimum of 150 with HFrEF). The study will also assess impact of the GDMT Clinic on health status, functional capacity, biomarker profiles, cardiac remodeling and cardiovascular events.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 300 (actual)
- First submitted
- 18 Nov 2024
- Start date
- 22 Sept 2023
- Primary completion date
- 22 Sept 2025
- Lead sponsor
- Massachusetts General Hospital
- Diseases
- Heart failure
- NCT number
- NCT06700213
What you commit to
- Study type: Observational
- Participants enrolled: 300
- From 22 Sept 2023 to the primary completion date, 22 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Advanced HF
- Inotropic support
- Transplant or MCS planned
- Enrolled in hospice or palliative care
Other illness
- Untreated severe valvular heart disease
- Life expectancy \<12 months due to non-CV disease
Lab values
- End-stage kidney disease
- eGFR \<15 mL/min/1.73m2 or on renal replacement therapy
Other
- Planned referral to the Advanced HF program
- Decompensated HF
- Pericardial constriction
- Hypertrophic cardiomyopathy
- Unwillingness or inability to take GDMT
- Pregnancy or breast feeding
Who the study is looking for
- Diagnosis of HF, including new onset disease
- Established cardiovascular follow up at MGH
- Receiving sub-optimal medical care defined as \<50% target doses of GDMT agents
- Age ≥18 years
- For HFpEF:
- Presence of structural heart disease (LAVi \>34 mL/Kg2, E/e' \>14, or LVH)
- Recent HF hospitalization or historical NT-proBNP \>300 pg/mL
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.